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Despite a good understanding of the disease and its treatments, asthma continues to place a large economic burden
on healthcare systems. As such, it is important to consider the economic impact of alternative therapeutic options
for the treatment of this condition to ensure that scarce resources are used in the most ecient manner possible.
Thus, the aim of asthma management from an economic perspective is to reduce the burden of this disease through
maximizing health gain with available resources.
A prospective economic analysis was conducted as part of a multicentre, randomized, double-blind, comparative
trial of salmeterol/fluticasone propionate combination product (SFC) 50/250 mg twice daily vs. budesonide (800mg
twice daily) in adults and adolescents with asthma who were symptomatic despite treatment with inhaled
corticosteroids at doses of 800–1200 mg day71. Treatment eectiveness was measured in terms of successfully-
treated weeks, defined as a 5% improvement in morning peak expiratory flow, episode-free days (a day without
the need for rescue medication, no nocturnal awakening or adverse events) and symptom-free days. Cost-
eectiveness analyses were performed using direct healthcare and drug costs, from the perspective of the Swedish
healthcare system (1998 prices), with appropriate sensitivity analyses to test the robustness of the findings.
Overall, SFC produced significantly higher (P50?001) proportions of successfully-treated weeks, episode-free
days and symptom-free days. Direct asthma management costs were similar between the two groups [SEK19?6
($US2?4) for SFC vs. SEK18?5 ($US2?2) for budesonide]. The cost per successfully-treated week was lower for SFC
than for budesonide [SEK204 ($US24?8) vs. SEK300 ($US36?4) per week], as were the costs per episode-free day
[SEK51?1 ($US6?2) vs. SEK75?1 ($US9?1) per day] and symptom-free day [SEK42?2 ($US5?1) vs. SEK53?0
($US6?4) per day]. Incremental cost-eectiveness ratios showed that the additional costs to achieve additional
benefits with SFC were minimal. Costs per additional successfully-treated week, symptom-free day and episode-free
day with SFC were SEK31?6 ($US3?9), SEK9?2 ($US1?1) and SEK7?7 ($US0?9), respectively, relative to
budesonide. Sensitivity analysis showed that the results were stable over a wide range of assumptions. The results
suggest that SFC is a more cost-eective treatment than budesonide in the management of moderate to severe
asthma.
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0954-6111/00/070724+09 $35?00/0most ecient way possible. Dierent therapeutic alterna-
tives will have diering implications both in terms of costs
and treatment outcomes. For example, a particular
therapeutic intervention may be clinically more eective
than an alternative therapy, but it may also result in
increased costs. In order to better inform decision-makers
on how to value possible treatment options, economic
techniques such as cost-eectiveness analyses are often used
to enable net changes in costs and outcomes to be explicitly
quantified. By attempting to maximize health gains and# 2000 HARCOURT PUBLISHERS LTD
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are particularly important in diseases such as asthma which
place a high burden on the patient, healthcare system and
society due to high morbidity, costs of regular and acute
management of the disease and reduced productivity.
In asthma, a significant proportion of the costs are due to
consequences of poor disease control, including exacerba-
tions requiring inpatient or emergency room treatment. The
total costs of asthma in the U.S.A. have been estimated to
be $US5?8 billion, with emergency care, physician visits and
medications representing the majority of these costs (1).
According to current data, the total cost of asthma in
Sweden amounts to SEK3 billion annually (2). Improving
asthma control through eective management strategies
will not only reduce morbidity and improve the patient’s
quality of life, but may also reduce costs associated with
managing acute exacerbations. It is therefore important to
conduct economic evaluations on new and existing asthma
treatments in order to evaluate the impact on costs and
treatment outcomes.
One of the reasons for high levels of morbidity and the
considerable costs of dealing with the consequences of poor
asthma control is under-utilization of inhaled steroids. The
clinical role of inhaled steroids in asthma is well established
due to the inflammatory nature of the disease. Recently,
studies have demonstrated that inhaled steroid therapy is
associated with a reduced risk of asthma-related hospita-
lization (3) as well as primary care and outpatient clinic
visits (4) and may be a cost-eective treatment intervention
in adults and children (5,6).
Of the available inhaled steroids, fluticasone propionate
has been shown to be at least as eective as beclomethasone
dipropionate and budesonide when administered at half the
dosage in adults and children with mild to moderate or
severe asthma (7–14). Salmeterol, a long-acting inhaled b2-
agonist, improves pulmonary function and symptom control
when used on a regular basis in adults and children with
asthma (15–19). Recent studies have demonstrated that the
addition of a long-acting b2-agonist is clinically more
eective (20–25) and cost-eective (26,27) than doubling
the dose of inhaled steroid in symptomatic asthma patients.
Based on this complementary role, a new dry powder inhaler
containing both salmeterol and fluticasone propionate has
recently been developed. This combination has been shown
to be at least as eective and safe as the two drugs co-
administered individually (28) and is more eective than the
individual drugs alone in achieving asthma control (29–31).
The present analysis was therefore undertaken to
determine the relative cost-eectiveness of salmeterol/
fluticasone propionate combination product vs. an inhaled
steroid (budesonide) alone in adults and adolescents with
moderate to severe asthma.
Methods
CLINICAL STUDY DESIGN
This economic analysis was based upon a multicentre,
randomized, double-blind, double-dummy, parallel-grouptrial, in which patients (aged 12 years) with asthma who
remained symptomatic on current doses of inhaled corti-
costeroids (800–1200 mg day71 of beclomethasone dipro-
pionate/budesonide or 400–800 mg day71 of fluticasone
propionate) were treated with either salmeterol/fluticasone
propionate combination product [SFC] 50/250mg twice
daily or budesonide 800mg twice daily for 24 weeks (32).
Study medication was given via DiskusTM/AccuhalerTM
inhaler (SFC) and via a breath actuated dry powder inhaler
(budesonide). Rescue medication was provided in the form
of salbutamol via a pressurized metered-dose inhaler
(100mg actuation71). Patients were not permitted to take
any other long-acting b2-agonists or theophyllines through-
out the study.
The treatment options compared in this study reflect a
clinically important step in the decision pathway when
clinicians are choosing between increasing the corticoster-
oid dose or adding in a long-acting b2-agonist for patients
with asthma who remain uncontrolled on their existing dose
of corticosteroid.
Effectiveness outcomes
A number of outcome measures were used to determine
treatment eectiveness for the purpose of economic analysis
in order to reflect the multiple aims of good asthma
management. These included the proportions of success-
fully-treated weeks, episode-free days and symptom-free
days.
A successfully-treated week was one in which the
patient’s mean morning peak expiratory flow (PEF),
predicted for age, sex and height, improved by 5% from
baseline. Patients withdrawn from the study due to an
asthma-related adverse event or lack of eectiveness were
assumed to have experienced no successfully-treated weeks
from the time of withdrawal until the end of the study.
Those patients who discontinued treatment because of
other reasons were assumed to have rates of success at the
mean rate for the treatment arm as a whole.
An episode-free day is a composite measure of eective-
ness, defined as a day without an asthma attack, need for
rescue medication or sleep disturbance caused by asthma
and the absence of an adverse event (33). A symptom-free
day was achieved when the patient reported no symptoms
over a 24-h period. In the event of early study withdrawal,
the same criteria as outlined above for evaluation of
successfully-treated weeks was also applied to the other
eectiveness parameters.
Evaluation of costs of asthma management
The economic analysis was conducted from the perspective
of the Swedish healthcare system. Calculation of the direct
costs of asthma management were based on resources
consumed (drug and non-drug costs) during the 24-week
treatment phase of the study. The following healthcare
*May 1999 exchange rates
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trial for all patients:
ii(i) hospital contacts (emergency room visits, intensive
care unit days, inpatient days and outpatient clinic
visits);
i(ii) general practitioner contacts (home and oce/
practice visits, telephone calls);
(iii) medications (study drugs, rescue medications and
other asthma-related prescription drugs. Asthma-
related prescription drugs included any medications
that were taken by patients during the treatment
period of the study to treat asthma symptoms or
acute exacerbations and included bronchodilators,
oral steroids and antibiotics).
Early study withdrawals were assigned a constant mean
daily cost following withdrawal, based upon the same rate
as those patients still in the trial in the same treatment
group. Unit costs for resource utilization and medications
were expressed in 1998 Swedish Krona (SEK) and were
derived from Swedish government statistics (34,35).
ECONOMIC ANALYSIS
Mean cost-eectiveness ratios were calculated by dividing
mean direct costs per patient by the rate of success for each
treatment and for each measure of eectiveness (thus, the
mean cost per successfully-treated week, symptom-free day,
etc was calculated for each treatment). Mean cost-
eectiveness ratios give an indication of the average cost
of achieving a given outcome with each treatment.
However, in informing decision-makers, incremental cost-
eectiveness ratios (ICERs) are more meaningful as they
evaluate the net dierence in cost and eects between the
treatment and essentially evaluate the economic impact of
switching from treatment A to treatment B. Therefore,
ICERs were calculated for each outcome measure by
dividing the dierence in costs of treatment between SFC
and budesonide by the dierence in the rate of eectiveness
(for example, the dierence in the proportion of symptom-
free days between the treatments).
Statistical analysis
Intention-to-treat population data were used in the
statistical analysis. Between-group dierences for the
eectiveness parameters were evaluated using pair-wise
comparisons. Between group dierences in the proportions
of successfully-treated weeks, symptom-free days and
episode-free days were evaluated using the Van Elteren
extension to the Wilcoxon rank sum test. For all analyses,
P50?05 was considered significant. A non-parametric
‘Bootstrap’ technique was used to calculate the 95%
confidence interval (CI) for the ICERs (36).
Sensitivity analysis
For successfully-treated weeks, the impact of dierences in
eectiveness between the SFC and budesonide treatmentgroups was assessed by redefining the percentage improve-
ment in PEF required to achieve a success from 1 to 10% in
1% increments (the base-case analysis was a 5%
improvement). For the remaining eectiveness parameters,
a sensitivity analysis was conducted using two scenarios.
The first scenario (best case) assumed that all patients
prematurely withdrawn from the study were symptom-free
and episode-free from the time of withdrawal; the second
scenario (worst case) assumed that all days subsequent to
premature withdrawal from the study were symptomatic or
were not episode-free from the time of withdrawal.
Results
A total of 353 patients with symptomatic moderate to
severe asthma were included in the study. There were no
statistically significant dierences in demographics and
clinical characteristics between the two treatment groups at
baseline (Table 1).
In terms of treatment eectiveness, patients in the SFC
treatment arm had significantly higher proportions of
successfully-treated weeks, episode-free days and symp-
tom-free days throughout the treatment period (Fig. 1).
Such improvements were paralleled by results from the
primary clinical analysis (32). Significantly higher adjusted
mean morning PEF values were observed over the 24-weeks
treatment period among those treated with SFC compared
with the budesonide group (406 l min71 vs. 380 l min71;
P50?001). Analysis of other patient diary data, including
evening PEF values, daily symptom scores, use of rescue
medication and patient satisfaction with treatment, also
favoured SFC over budesonide despite the higher steroid
dose in this group (32).
USE OF HEALTHCARE RESOURCES
Use of healthcare resources during the study (excluding
medications) is summarized in Table 2. Asthma-related
primary and secondary care visits were similar across the
two groups. When drug treatment costs were also
considered, mean total direct healthcare costs per patient
per day were very similar between the two groups, SEK19?6
($US2?38)* in the SFC arm compared with SEK18?5
($US2?24) in the budesonide arm (Fig. 2).
COST-EFFECTIVENESS ANALYSIS
The mean cost per successfully-treated week was lower for
SFC than for budesonide (Table 3), indicating that a week
of improved lung function with SFC was achieved at a
lower mean cost than with budesonide. The ICER was
calculated to determine the additional healthcare costs that
must be paid to achieve this additional benefit. This ratio
was SEK31?6 (Table 3), indicating that it costs, on average,
an extra SEK32 ($US3?9) for an additional week of
improved lung function with SFC relative to budesonide.
TABLE 1. Summary of baseline demographic and clinical characteristics
Treatment group
Parameter Salmeterol/fluticasone propionate
(n=180)
Budesonide
(n=173)
Mean age, years (SD) 45 (15) 48 (16)
Males: females, % 50:50 50:50
Duration of airways disease, % patients*
55 years 24 23
5 to 510 years 17 16
10 to 515 years 13 13
415 years 45 49
Mean morning PEF during 2-week run-in period, l min71 (SD)
Week 1 363 (95) 356 (95)
Week 2 361 (93) 358 (96)
*Percentages may not total 100% because of rounding.
PEF: peak expiratory flow; SD: standard deviation.
FIG. 1. Summary of the eectiveness of salmeterol/
fluticasone combination product (50/250 mg twice daily)
vs. budesonide (800mg twice daily) in patients with
moderate to severe asthma, previously treated with
inhaled corticosteroids; *P50?001 vs. budesonide. &
Salmeterol/fluticasone propionate; & budesonide.
FIG. 2. Direct asthma treatment costs per patient per day
over 24 weeks. Patients who were withdrawn from the
study were assumed to continue to use resources at the
same mean rate as those patients still in the trial in their
respective treatment arm. & Relief medication;
Concurrent therapy; & primary care; study drug;
hospital.
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day were lower for salmeterol/fluticasone propionate than
for budesonide [SEK51?1 ($US6?20) vs. SEK75?1
($US9?11) and SEK42?2 ($US5?12) vs. SEK53?0
($US6?43), respectively]. The costs for achieving anadditional episode-free day and symptom-free day with
SFC were SEK7?7 ($US0?93) and SEK9?2 ($US1?12) per
day, respectively (Table 3). All CIs for the three eective-
ness endpoints crossed zero, which does not indicate a lack
of statistical significance in this instance. This indicates that
at the negative end of the CI, improvements in eectiveness
were achieved at a lower overall cost with SFC. In this
scenario, budesonide is said to be dominated by SFC. The
95% CI for the symptom-free day endpoint therefore
indicates that the true cost for an additional day without
asthma symptoms with SFC compared to budesonide lies
somewhere between overall cost savings (SFC is the
TABLE 2. Summary of asthma-related healthcare resource utilization (excluding medications) throughout the 24-week
treatment period
Treatment group
Healthcare resource utilization* Salmeterol/fluticasone propionate
(n=180)
Budesonide
(n=173)
Hospital contacts
Emergency room visits 2 (2) 2 (2)
Intensive care unit days 0 0
General ward days 3 (1) 7 (1)
Other{ (2) (0)
Outpatient clinics 25 (17) 29 (20)
General practitioner contacts
Home visits 22 (17) 19 (15)
Clinic visits 36 (26) 24 (19)
Telephone contacts 14 (13) 19 (17)
*Number of patients are given in parentheses.
{Patients treated as an inpatient, but data missing in terms of duration and department (i.e. emergency, intensive care unit or
general ward). These patients were assumed to be inpatients on a general medical ward, and the data were costed accordingly.
FIG. 3. Sensitivity analysis for successfully-treated weeks. The dierences in improvement in morning peak expiratory flow
were varied in 1% increments from 1 to 10%, with a 5% improvement being the base-case scenario. All dierences
between treatment groups remained statistically significant (P50?001) in favour of salmeterol/fluticasone propionate for
each increment tested in the sensitivity analysis. & SFC 50/250 mg; & BUD 800mg.
728 B. LUNDBA¨CK ET AL.dominant strategy) and an additional SEK9?2 ($US1?12)
per additional symptom-free day gained.
SENSITIVITY ANALYSIS
A successfully-treated week was defined as a 5% mean
weekly improvement in mean morning PEF compared tobaseline predicted values; however, this criterion is some-
what arbitrary. When the criterion for successfully-treated
week was varied in 1% increments as part of a sensitivity
analysis, the statistical significance (P50?001) of the results
continued to favour SFC over the range of the sensitivity
analysis, indicating that the assumption was robust
(Fig. 3).
TABLE 4. Sensitivity analyses for eectiveness parameters, based on the outcome of patients prematurely withdrawn from the
study* [Data are expressed as mean proportion (SD)]
Treatment group P-value
Parameter Salmeterol/fluticasone propionate Budesonide
Best-case scenario{
Episode-free days 43?9 (32?9) 30?8 (31?4) 50?001
Symptom-free days 51?6 (32?5) 40?5 (34?9) 50?001
Worst-case scenario{
Episode-free days 35?9 (32?0) 23?2 (28?7) 50?001
Symptom-free days 43?5 (32?6) 32?9 (33?9) 50?001
*Base-case analysis assumed that all such patients were symptomatic or not episode-free if withdrawn due to an asthma-
related event, but otherwise continued to accrue treatment successes at the same mean rate if withdrawn for other reasons.
{Assumes all subsequent days were symptom-or episode-free for patients prematurely withdrawn from the study.
{Assumes all subsequent days were not symptom-or episode-free for patients prematurely withdrawn from the study.
SD: standard deviation.
TABLE 3. Mean cost-eectiveness and incremental cost-eectiveness ratios
Treatment group
Cost-eectiveness ratio (SEK) Salmeterol/fluticasone propionate Budesonide
Cost per successfully-treated week 204 ($US 24?75) 300 ($US 36?40)
Incremental cost-eectiveness ratio (95% CI) 31?6 (737?6*, 113?6)
Cost per episode-free day 51?1 ($US 6?20) 75?1 ($US 9?11)
Incremental cost-eectiveness ratio (95% CI) 7?7 (77?8*, 29?5)
Cost per symptom-free day 42?2 ($US 5?12) 53?0 ($US 6?43)
Incremental cost-eectiveness ratio (95% CI) 9?2 (711?8*, 47?8)
*Negative value denotes that improvements in eectiveness were achieved at a lower overall cost with salmeterol/fluticasone
propionate
CI: confidence interval.
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and episode-free days, using a best-case/worst-case scenar-
io. The results demonstrate that the base-case assumption
was rigorous, as they were always significantly in favour of
SFC, regardless of the assumption used (Table 4).
The cost-eectiveness results were also subjected to
sensitivity analysis. The cost-eectiveness ratios for success-
fully-treated weeks continued to favour SFC over budeso-
nide, and the ICER remained relatively constant, when the
improvement in morning PEF was varied from 1 to 10%
(Table 5). Similar findings were observed during sensitivity
analysis of the cost-eectiveness ratios and ICERs for
symptom- and episode-free days, with the results remaining
robust to changes in underlying assumptions (Table 6).
Discussion
In this study a range of endpoints were used in the cost-
eectiveness analysis as there is no single outcome measurefor asthma that reflects the full range of treatment benefits
for patients, clinicians and healthcare decision-makers. The
range of endpoints we used were chosen to reflect the
multiple aims of asthma management, including improve-
ment in asthma symptoms, adverse events, b2-agonist use,
nocturnal awakenings (episode-free day) and improvement
in lung function. The second criterion for selection was that
three of the endpoints had previously been reported in
economic evaluations in asthma (6,33,37).
For patients who remain uncontrolled on inhaled
corticosteroid therapy alone, (as was the case with patients
recruited into this study), asthma management guidelines
specifically recommend two possible treatment options,
namely the addition of a long-acting b2-agonist, or an
increase in the ICS dose. The design of this study allows
comparison of precisely these two treatment options,
providing an answer to a question that regularly faces
physicians, that is which management option should be
selected, given that both are recommended by guidelines? In
TABLE 5. Sensitivity analyses for cost-eectiveness ratios, based on successfully-treated weeks
Mean cost per successfully-treated week (SEK)
Improvement in
morning PEF
Salmeterol/fluticasone
propionate
Budesonide Incremental cost-eectiveness
ratio (SEK; 95% CI)
 1% 169 217 35?5 (735?3*, 120?7)
 2% 175 232 33?8 (741?1*, 109?9)
 3% 183 250 32?6 (738?4*, 101?7)
 4% 193 272 32?1 (733?0*, 103?9)
 5%{ 204 300 31?6 (737?6*, 113?6)
 6% 219 335 31?6 (736?4*, 103?6)
 7% 236 365 33?3 (734?5*, 111?6)
 8% 251 403 33?5 (733?5*, 116?0)
 9% 266 449 33?4 (737?7*, 117?6)
 10% 283 507 33?0 (744?5*, 110?4)
*Negative value denotes that improvements in eectiveness were achieved at a lower overall cost with salmeterol/fluticasone
propionate.
{Base-case scenario.
CI: confidence interval; PEF: peak expiratory flow.
TABLE 6. Sensitivity analyses for cost-eectiveness ratios for episode-free days and symptom-free days, based on the outcome
of patients prematurely withdrawn from the study*
Treatment group
Parameter (SEK) Salmeterol/fluticasone propionate Budesonide
Best-case scenario{
Cost per episode-free day 44?6 60?2
Incremental cost-eectiveness ratio (95% CI) 8?0 (712?4{, 31?7)
Cost per symptom-free day 38?0 45?7
Incremental cost-eectiveness ratio (95% CI) 9?5 (716?3{, 45?0)
Worst-case scenario}
Cost per episode-free day 54?5 79?8
Incremental cost-eectiveness ratio (95% CI) 8?3 (79?7{, 36?9)
Cost per symptom-free day 45?0 56?3
Incremental cost-eectiveness ratio (95% CI) 9?9 (713?1{, 51?6)
*Base-case analysis assumed that all such patients were symptomatic or not episode-free if withdrawn due to an asthma-
related event, but otherwise continued to accrue treatment successes at the same mean rate if withdrawn for other reasons.
{Assumes all subsequent days were symptom-or episode-free for patients prematurely withdrawn from the study.
{Negative value denotes that improvements in eectiveness were achieved at a lower overall cost with salmeterol/fluticasone
propionate.
}Assumes all subsequent days were not symptom-or episode-free for patients prematurely withdrawn from the study.
CI: confidence interval.
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complementary roles of inhaled long-acting b2-agonists and
inhaled steroids, (20–25) treatment with SFC 50/250 mg
twice daily was significantly more eective than using
higher doses of corticosteroids alone. Thus, the proportion
of successfully-treated weeks in the SFC group was 56%higher than among those treated with budesonide 800 mg
twice daily. Similar findings were observed for the propor-
tion of episode-free days and symptom-free days.
The improved eectiveness of SFC relative to budesonide
was achieved at a similar overall cost. On average,
treatment with SFC was SEK1?1 ($US0?12) per day more
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increases in eectiveness were reflected in the favourable
cost-eectiveness analyses. Despite the slightly higher study
drug acquisition costs, the costs per successfully-treated
week, episode-free day and symptom-free day were
consistently lower for SFC than for budesonide. ICERs
showed that the additional costs to produce an additional
successfully-treated week, episode-free day or symptom-
free day were SEK31?6 ($US3?83) per week, SEK7?7
($US0?93) per day and SEK9?2 ($US1?12) per day,
respectively.
In order to interpret these data meaningfully, ICERs
need to be judged in terms of an assessment of the value of
the respective improvement compared to other treatment
alternatives. The ratios obtained in the current study
appear to be reasonable in light of the level of gain in
improvement in asthma control attained with the combina-
tion product. For example, the incremental cost per
symptom-free day was considerably lower than the $US5
(SEK43) reported by Rutten-van Molken et al. (6). This
was regarded as an acceptable premium to pay for a day
without asthma symptoms and on this basis, it can
therefore be reasonable to assume that an additional
SEK9?2 ($US1?12) for a day without troublesome asthma
symptoms is highly acceptable. It should also be remem-
bered that although treatment benefits are presented
independently in the cost-eectiveness analysis, the multiple
benefits will in fact occur simultaneously. Thus, using a
disaggregated cost-consequence approach, results from this
study suggest that for an extra SEK1?1 per day relative to
budesonide, patients treated with SFC had 24% more
successfully-treated weeks, 11% more symptom-free days
and 12% more episode-free days. This represents an
additional expenditure per patient over the 24 weeks of
the study of SEK184 ($US22?4) to achieve these additional
benefits with SFC relative to budesonide. In light of these
findings, it can be argued that the small additional
expenditure associated with treating asthma patients with
SFC 50/250mg twice daily is justified in terms of the
considerably greater treatment benefits compared with
budesonide 800mg twice daily. Sensitivity analyses con-
firmed that these findings were robust over a wide range of
assumptions.
As with all clinical trial-based economic analyses, the
highly controlled environment, close patient monitoring
and likely high levels of patient compliance may result in an
underestimation of the true economic consequences of poor
asthma control. However, on the positive side, the 6-month
duration of this study gave a reasonable period over which
to follow patients and collect healthcare resource utilization
data. A further limitation is the relatively small number of
evaluations in the literature with which to compare the
findings of this study. Clearly, there is a need for further
economic evidence of alternative asthma therapies if
economic evaluation is to play a greater role in decision-
making in asthma.
In conclusion, these results suggest that SFC 50/250 mg
twice daily is more cost-eective than budesonide 800 mg
twice daily in the treatment of adults and adolescents with
moderate to severe asthma who remain symptomatic ontheir current doses of inhaled corticosteroid (beclometha-
sone dipropionate/budesonide 800–1200 mg day71 or fluti-
casone propionate 400–800 mg day71).
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